Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 866-871

  Phillips, David Richard ^a   Hay, Phillip ^a,b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiretrovirals; HAART; HIV; Lipoatrophy; Lipodystrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; URIDINE; ZIDOVUDINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; EVIDENCE BASED MEDICINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; PATHOGENESIS; PLASTIC SURGERY; RISK BENEFIT ANALYSIS; SUBCUTANEOUS FAT; TREATMENT DURATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS;

EID: 54549083463     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn318     Document Type: Editorial

References (46)

1. Van Griensven J, De Naeyer L, Mushi T et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line anti-retroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101: 793-8.
2. Fat distribution in women with HIV infection; from the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). J Acquir Immune Defic Syndr 2006; 42: 562-70.
3. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
4. Brinkman K, Smeitink JA, Romijn JA et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
5. Mallal S, John M, Moore CB et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-16.
6. Moyle GJ, Baldwin C, Langroudi B et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-8.
7. Smith DE, Carr A, Law M et al. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: The PIILR extension study. AIDS 2002; 16: 2489-91.
8. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-intected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004; 18: 1029-36.
9. McComsey G, Ward DJ, Hessenthaler SM et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70.
10. McComsey G, Maa JF. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003; 13: 539-42, 559.
11. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
12. Murphy R, Zhang J, Hafner R et al. Peripheral and visceral fat changes following a treatment switch to a nonthymidine analog or nucleoside-sparing regimen in patients with peripheral lipoatrophy: 48 week final results of ACTG A5110, a prospective, randomized, multicenter clinical trial. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 755. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
13. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
14. Podzamczer D, Ferrer E, Sanchez P et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139-47.
15. Martinez E, Arranz A Podzamczer D et al. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvade®) vs. abacavir plus lamivudine (Kivexa®) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study. In: Abstracts of the Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007. Abstract WESS102.
16. Walker UA, Brinkman K. An argument for mitochondrial toxicity in highly active antiretroviral therapy-induced lipoatrophy. AIDS 2001; 15: 1450-2.
17. Buffet M, Schwarzinger M, Amellal B et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol 2005; 33: 60-4.
18. McComsey GA, Walker UA. Role of mitochondria. in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion 2004; 4: 111-8.
19. Hansen AB, Undegaard B, Obel N et al. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med 2006; 7: 38-45.
20. Bogner JR, Vielhauer V, Beckmann RA et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001; 27: 237-44.
21. Fisher M, Moyle G, Ebrahimi R et al Switching from Combivir (CBV, AZT/3TC) to Truvada (TVD, TDF/FTC) maintains viral suppression, prevents and reverses limb fat loss, and improves biochemical parameters: Results of a 48 week randomised study. In: Abstracts of the Eleventh European AIDS Conference, Madrid, Spain, 2007. Abstract PS5/7.
22. McComsey G, Lonergan T, Fisher R. Improvements in lipoatrophy are observed after 24 weeks when stavudine is replaced by either abacavir or zidovudine. In: Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002. Abstract 701.
23. Saint-Marc T, Partisani M, Poizot-Martin I et al. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy. In: Abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000. Abstract 52. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
24. Clark A. Improvement of facial lipoatrophy after substitution of stavudine. In: Abstracts of the Second International Workshop on Adverse Drug Reactions and Lipodystrophy, Toronto, Canada, 2000. Abstract P85.
25. García-Benyas T, Blanco F, Gómez JM et al. Replacement of stavudine by abacavir does not ameliorate lipoatrophy in HAART recipients. In: Abstracts of the First International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina 2001. Abstract 491.
26. Arribas J, Pozniak AL, Gallant JE et al. Three-year safety and efficacy of emtricitabine (FTC)/tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (AZT/3TC) and EFV in antiretroviral treatment-nalve patients. In: Abstracts of the Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007. Poster #WEPEB029.
27. Cameron DW, da Silva B, Arribas J et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV + ZDV/3TC. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, 2007. Abstract 44. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
28. Valantin MA, Lanoy E, Bentata M et al. Maintenance of virological suppression and impact on lipoatrophy of NRTI-sparing regimens in antiretroviral-treated patients: NONNUKE ANRS 108 study. In: Abstracts of the Tenth European AIDS Conference, Dublin, Ireland, 2005 Abstract 5/2.
29. Fischl M, Bassett R, Collier A et al. Randomized, controlled trial of lopinavir/ritonavir + efavirenz vs efavirenz + 2 nucleoside reverse transcriptase inhibitors following a first suppressive 3- or 4-drug regimen in advanced HIV disease. In: Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 162. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
30. Kim M, Leclercq P, Cervera P et al. A 6 month ART interruption in HIV-infected patients improves adipose tissue morphology and gene expression (ANRS EP29 Lipostop). In: Abstracts of the Eighth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Francisco, CA, 2006. Abstract 5.
31. Hittinger G, Poggi C, Beyssac JM et al. Lipodystrophy syndrome in HIV infected patients taking a NRTI combination, partial reversion with a one-week on/off treatment, oxygen assay, results at 48 weeks. In: Abstracts of the Fifteenth International AIDS Conference, Bangkok, Thailand, 2004. Abstract WePeB5963.
32. El-Sadr W, Neaton J. Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: Results of the SMART study. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 106LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
33. Carr A, Workman C, Carey D et al. No effect of rosiglitazone for HIV-1 lipoatrophy: A randomised, double-blind, placebo-controlled trial. Lancet 2004; 363: 429-38.
34. Slama L, Lanoy E, Valentin M et al. Effect of pioglitazone on HIV-1 lipoatrophy: A randomised, double-bind, placebo-controlled trial (ANRS113). In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 151LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
35. Mallon PWG, Miller J, Kovacic JC et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study. AIDS 2006; 20: 1003-10.
36. Macallan DC, Mandalia S, Panayiotakopoulos G et al. Comparison of the effects on body composition of rosiglitazone, pravastatin, and growth hormone alone and in combination in the HIV-associated lipoatrophy treatment (HALT) study. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract H-1897. American Society for Microbiology, Washington, DC, USA.
37. Koutkia P, Canavan B, Breu J et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: A randomized controlled trial. JAMA 2004; 292: 210-8.
38. Sutinen J, Walker UA, Sevastianova K et al. Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy (HAL) - a randomized, placebo-controlled trial. In: Abstracts of the Seventh International Workshop on Adverse Events and Lipodystrophy in HIV Dublin, Ireland, 2005. Abstract 7.
39. Sommer B, Sattler G. Current concepts of fat graft survival: Histology of aspirated adipose tissue and review of the literature. Dermatol Surg 2000; 26: 1159-66.
40. Oyafuso LK, Serra MS, Troppe BM. Polymethylmethacrylate (PMMA) for facial lipoatrophy treatment: 5 years follow up. In: Abstracts of the Fifteenth International AIDS Conference, Bangkok, Thailand, 2004. Abstract MoOrB1060.
41. Esch P. Caring for HIV-positive and aging patients with associated facial lipoatrophy. Plast Surg Nurs 2006; 26: 17-23.
42. Berlin A, Cohen JL, Goldberg DJ. Calcium hydroxylapatite for facial rejuvenation. Semin Cutan Med Surg, 2006; 25: 132-7.
43. Valantin MA, Aubron-Olivier C, Ghosn J et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-intected patients: Results of the open-label study VEGA. AIDS 2003; 17 2471-7.
44. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience. Dermatol Surg 2006; 32: 1336-45.
45. Dubé M, Komarow L, Mulligan K et al. DEXA outcomes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz or both plus dual nucleosides: Long-term results from A5005s, a substudy of ACTG 384. In: Abstracts of the Sixteenth International AIDS Conference, Toronto, Canada, 2006. Abstract WEPE0167.
46. Zuger A. ACTG 5142 compares class-sparing regimens in treatment-naive patients: Report from the XVI International AIDS Conference. AIDS Clin Care 2006; 18: 98.